Skip to Content

Join the 'Abatacept' group to help and get support from people like you.

Abatacept News

New Treatments Helping Kids With Juvenile Arthritis

Posted 20 Jul 2016 by Drugs.com

WEDNESDAY, July 20, 2016 – New treatments for juvenile arthritis offer hope to children with the chronic autoimmune condition, doctors say. Scientists are still working to understand what causes juvenile arthritis and how to stop its progression. But, kids coping with its effects have reason to be optimistic, according to Dr. Nikolay Nikolov, a rheumatologist and clinical team leader at the U.S. Food and Drug Administration. "We don't have a cure for juvenile arthritis – we're not there yet," Nikolov said in an FDA news release. "But we're making progress." But it's important to note that the drugs aren't risk-free. Juvenile arthritis is one of the most common chronic childhood conditions, affecting nearly 300,000 children in the United States, according to the FDA. The disease causes the immune system to attack its own tissues, resulting in pain, swelling, tenderness and stiffness in ... Read more

Related support groups: Rheumatoid Arthritis, Aspirin, Ibuprofen, Humira, Advil, Enbrel, Motrin, Excedrin, Aggrenox, Orencia, Vicoprofen, Alka-Seltzer, Juvenile Rheumatoid Arthritis, Fiorinal, Advil PM, Excedrin Migraine, Actemra, Ecotrin, Advil Cold and Sinus, Fiorinal with Codeine

Kidney Woes Tied to Raised Cancer Risk, Study Finds

Posted 12 Nov 2015 by Drugs.com

THURSDAY, Nov. 12, 2015 – Kidney failure and having a kidney transplant may increase the risk for certain types of cancer, a new study suggests. Poor kidney function and immune system-suppressing drugs may be behind this increased risk, according to Elizabeth Yanik, of the U.S. National Cancer Institute, and colleagues. For the study, published in the Nov. 12 online edition of the Journal of the American Society of Nephrology, the researchers looked at data from more than 200,000 U.S. kidney transplant candidates and recipients. Along with finding that these patients are at increased risk for certain types of cancer, the investigators also identified clear patterns of risk associated with different types of treatment. However, the associations seen in the study do not prove cause-and-effect. The risk of kidney and thyroid cancers was especially high when kidney failure patients were on ... Read more

Related support groups: Cancer, Methotrexate, Renal Failure, CellCept, Gilenya, Tysabri, Xolair, Orencia, Imuran, Chronic Kidney Disease, Revlimid, Leflunomide, Arava, Azathioprine, Afinitor, Tecfidera, Mycophenolate Mofetil, Peritoneal dialysis, Benlysta, Aubagio

Gene Discoveries Could Help Rheumatoid Arthritis Treatment

Posted 28 Apr 2015 by Drugs.com

TUESDAY, April 28, 2015 – Genetic variations may hold clues to rheumatoid arthritis – suggesting not only who will develop the painful condition, but also predicting its severity and even who might die from it, a new study says. "Genetic factors predisposing to disease, to disease severity, and response to treatment will allow tailoring treatment to individual patients' needs," said lead researcher Dr. Sebastien Viatte, a research fellow at the University of Manchester in England. Using data from several sources on thousands of patients in the United Kingdom, researchers found that gene mutations at a location on a chromosome called HLA-DRBl were associated with rheumatoid arthritis severity and the response to treatment with tumor necrosis factor (TNF) inhibitor drugs. This study, Viatte said, is a potentially important first step toward personalized medicine for patients with the ... Read more

Related support groups: Rheumatoid Arthritis, Methotrexate, Humira, Enbrel, Remicade, Plaquenil, Hydroxychloroquine, Rituxan, Otezla, Imuran, Orencia, Rituximab, Cimzia, Juvenile Rheumatoid Arthritis, Leflunomide, Arava, Azathioprine, Simponi, Xeljanz, Infliximab

Some Arthritis Meds Cost Seniors Thousands Annually

Posted 21 Apr 2015 by Drugs.com

TUESDAY, April 21, 2015 – Arthritis medications known as biologic disease-modifying drugs can cost Medicare patients more than $2,700 in co-payments a year, a new report finds. Researchers say the tab is an immense burden on patients with disabling conditions such as rheumatoid arthritis, a chronic disorder that affects an estimated 1.3 million Americans. Biologic anti-rheumatic medications – which include drugs such as adalimumab (Humira), anakinra (Kineret) and etanercept (Enbrel) – have allowed patients to gain better control of rheumatoid arthritis when taken early in the course of disease, the researchers explained. But some of the new drugs top $20,000 annually, according to the April 21 online report in the journal Arthritis & Rheumatology. "Many patients face a growing and unacceptable financial burden for access to treatment," said study lead author Dr. Jinoos Yazdany of the ... Read more

Related support groups: Rheumatoid Arthritis, Methotrexate, Humira, Enbrel, Remicade, Plaquenil, Hydroxychloroquine, Rituxan, Imuran, Orencia, Otezla, Rituximab, Leflunomide, Arava, Azathioprine, Xeljanz, Infliximab, Adalimumab, Kineret, Etanercept

Arthritis Drug Could Benefit Some Kidney Disease Patients

Posted 8 Nov 2013 by Drugs.com

FRIDAY, Nov. 8 – A drug that is currently prescribed for rheumatoid arthritis also may be beneficial for patients with a common form of kidney disease that is difficult to treat and often leads to kidney failure, according to a small new study. Researchers said they also identified a way to help determine which patients would be most likely to benefit from the drug. The condition, called focal segmental glomerulosclerosis (FSGS), causes scar tissue to form in the kidneys' filtering units. Most people affected by the disease are also obese or have high blood pressure or diabetes. Although steroids and certain drugs that suppress the immune system help some people with FSGS, these treatments have long-term side effects that may outweigh the drug's benefits, the researchers said. "We identified abatacept as the first personalized, targeted treatment for kidney disease and specifically for ... Read more

Related support groups: Orencia, Abatacept, Focal Segmental Glomerulosclerosis

Newer Rheumatoid Arthritis Drugs Don't Raise Cancer Risk: Study

Posted 6 Sep 2012 by Drugs.com

THURSDAY, Sept. 6 – A new review finds that rheumatoid arthritis medications known as biologics don't raise the risk of cancer, contrary to what some previous research has suggested. Rheumatoid arthritis affects an estimated 1 percent of the general population, with women three times more likely to have it. Different from age-related osteoarthritis, rheumatoid arthritis is debilitating autoimmune disorder that causes inflammation of the lining of the joints. Biologics work by targeting specific parts of the immune system involved in the inflammation process. Previous studies have raised questions about whether the drugs might boost the risk of cancer. The new study appears in the Sept. 5 issue of the Journal of the American Medical Association. The researchers, led by a researcher at the University of Texas M.D. Anderson Cancer Center, looked at 63 randomized controlled trials of the ... Read more

Related support groups: Rheumatoid Arthritis, Humira, Enbrel, Remicade, Rituxan, Orencia, Rituximab, Cimzia, Simponi, Actemra, Infliximab, Adalimumab, Kineret, Etanercept, Golimumab, Certolizumab, Abatacept, Tocilizumab, Anakinra

U.S. Food and Drug Administration Approves Subcutaneous Formulation of Orencia (abatacept), a Proven Non-Anti-TNF Biologic for Adults with Moderate to Severe Rheumatoid Arthritis

Posted 1 Aug 2011 by Drugs.com

PRINCETON, N.J.--(BUSINESS WIRE)--Jul 30, 2011 - Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration (FDA) has approved a subcutaneous (SC) formulation of Orencia (abatacept) for the treatment of adults with moderate to severe rheumatoid arthritis (RA). Orencia is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. Orencia may be used as monotherapy or concomitantly with disease-modifying antirheumatic drugs (DMARDs) other than tumor necrosis factor (TNF) antagonists. Orencia should not be administered concomitantly with TNF antagonists. Orencia is not recommended for use concomitantly with other biologic RA therapy, such as anakinra. Orencia is the first and only biologic ... Read more

Related support groups: Rheumatoid Arthritis, Orencia, Abatacept

Ask a Question

Further Information

Related Condition Support Groups

Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis

Related Drug Support Groups

Orencia

Abatacept Patient Information at Drugs.com